|Articles|April 22, 2020

Dr. Rosevear: Practicing in a pandemic

Author(s)Benjamin P. Saylor, Strategic Content Lead

Henry Rosevear, MD, talks about how he and his practice are coping with the COVID-19 pandemic.

Henry Rosevear, MD, Urology Times® Clinical Practice Board member and blogger, has written thoughtfully and eloquently about the COVID-19 pandemic in recent blog posts for UrologyTimes.com. Urology Times® spoke to him on April 7 about how he and his practice are coping with the present situation. Also see: COVID-19 and urology: What you can do How ‘elective’ surgery is defined during the COVID-19 crisis Telemedicine in urology: A crash course during the COVID-19 pandemic

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

September 30th, 2026

Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.

September 30th, 2026

Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.

September 30th, 2026

FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program

The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.

September 29th, 2026

Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR

In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.

September 29th, 2026

Armine K. Smith, MD, on addressing sexual health in modern bladder cancer care

Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.

September 28th, 2026

SBRT, prostatectomy show comparable long-term disease control in PACE-A trial

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.

September 28th, 2026

A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancer

Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.